British journal of pharmacology | 2021

Sex differences in the effect of chronic delivery of the buprenorphine analog BU08028 on heroin relapse and choice in a rat model of opioid maintenance.

 
 
 
 
 
 
 
 
 
 

Abstract


BACKGROUND AND PURPOSE\nMaintenance treatment with opioid agonists (buprenorphine, methadone) decreases opioid use and relapse. We recently modeled maintenance treatment in rats and found that chronic delivery of buprenorphine or the mu opioid receptor (MOR) partial agonist TRV130 decreases relapse to oxycodone seeking and taking. Here, we tested the effect of the buprenorphine analog BU08028 on different heroin relapse-related measures and heroin vs. food choice.\n\n\nEXPERIMENTAL APPROACH\nFor relapse assessment, we trained male and female rats to self-administer heroin (6-h/d, 14-d) in context A and then implanted osmotic minipumps containing BU08028 (0, 0.03, or 0.1 mg/kg/d). We then tested the effect of chronic BU08028 delivery on (1) incubation of heroin seeking in a non-drug context B, (2) extinction responding reinforced by heroin-associated discrete cues in context B, (3) reinstatement of heroin seeking induced by reexposure to context A, and (4) reacquisition of heroin self-administration in context A. For choice assessment, we tested the effect of chronic BU08028 delivery on heroin vs. food choice.\n\n\nRESULTS\nChronic BU08028 delivery decreased incubation of heroin seeking. Unexpectedly, BU08028 increased reacquisition of heroin self-administration selectively in females. Chronic BU08028 had minimal effects on context-induced reinstatement and heroin vs. food choice in both sexes. Finally, exploratory post-hoc analyses suggest that BU08028 decreased extinction responding selectively in males.\n\n\nCONCLUSIONS AND IMPLICATIONS\nChronic BU08028 delivery had both beneficial and detrimental sex-dependent effects on different triggers of heroin relapse and minimal effects on heroin choice in both sexes. Results suggest that BU08028 will not be an effective opioid maintenance treatment in humans.

Volume None
Pages None
DOI 10.1111/bph.15679
Language English
Journal British journal of pharmacology

Full Text